For the full year, our Zacks Consensus Estimates are projecting earnings of $6.35 per share and revenue of $42.01 billion, which would represent changes of +35.39% and +60.68%, respectively, from the prior year. These recent revisions tend to reflect the evolving nature of short-term business trends. Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know (Zacks) 21.12.20 The Zacks Analyst Blog Highlights: Tesla, Home Depot, Netflix, McDonald's and Bristol-Myers Squibb (Zacks) Bristol Myers Squibb Company (BMY) - free report >>. For Immediate Release . To learn more, click here. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Dec-26-20 01:34AM : It Might Not Be A Great Idea To Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Next Dividend. For Immediate Release . 12 months ago. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Zacks.com 4 days ago. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.48 as of yesterday's close. Click to get this free report BMY is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Privacy Policy | No cost, no obligation to buy anything ever. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Dec-28-20 06:59AM : European Medicines Agency Validates Bristol Myers Squibbs Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment. BMY is currently a Zacks Rank #3 (Hold). New York-based Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases. The scores are based on the trading styles of Value, Growth, and Momentum. Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS 11/18/2020 District’s new fire chief aims to stay the course, but confronts challenges with pandemic, budget ZacksTrade and Zacks.com are separate companies. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. * indicates the important links in the menu. No cost, no obligation to buy anything ever. The monthly returns are then compounded to arrive at the annual return. Delayed quotes by Sungard. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. These results would represent year-over-year changes of +33.05% and +60.23%, respectively. Zacks’ Single Best Pick to Double. The Zacks Rank has been called the Billion Dollar Secret. This change lagged the S&P 500's 0.57% gain on the day. BMY currently has a Zacks Rank of #3 (Hold). BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.24 per share and revenue of $41.89 billion. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Bristol-Myers Squibb (BMY) closed at $61.70 in the latest trading session, marking a +0.24% move from the prior day. The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank. For comparison, its … See all Medical - Biomedical and Genetics Peers. Want the latest recommendations from Zacks Investment Research? This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Want the latest recommendations from Zacks Investment Research? Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. in the Information. These revisions help to show the ever-changing nature of near-term business trends. Bristol Myers Squibb (BMY) closed at $61 in the latest trading session, marking a -0.7% move from the prior day. The Zacks Consensus EPS estimate has moved 0.41% higher within the past month. We expect an in-line return from the stock in the next few months. Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 9.67 right now. Our research shows that these estimate changes are directly correlated with near-term stock prices. View Bristol Myers Squibb Company BMY investment & stock information. Get the latest broker recommendations from Zacks Investment Research. December 30, 2020. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. BMY currently has a Zacks Rank of #3 (Hold). Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. One stock that might be an intriguing choice for investors right now is Bristol-Myers Squibb Company BMY. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Skip to content. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions. In 1978, our founder discovered the power of … BMY is currently a Zacks Rank #3 (Hold). Get the latest Bayerische Motoren Werke AG BAMXF detailed stock quotes, stock … BMY is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. PFE: 36.81 (+0.19%) MRK: 81.80 (+1.50%) BMY: 62.03 (+0.18%) CORT: 26.16 (-0.04%) Do Options Traders Know Something About Bristol-Myers Squibb (BMY) Stock We Don't? This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. Zacks’ Single Best Pick to Double. Investors might also notice recent changes to analyst estimates for BMY. BMY: Bristol Myers Squibb Company broker recommendations. If you do not, click Cancel. Recent stocks from this report have soared up to +178.7% in 3 months. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.77% per year. Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's … The technique has proven to be very useful for finding positive surprises. Zacks Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. Today, you can download 7 Best Stocks for the Next 30 Days. . Bristol-Myers Squibb Company (BMY) Stock Price: $61.38 USD-0.65 (-1.05%) Updated January 4, 4:00 PM EST - Market closed. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from Zacks. Do Options Traders Know Something About Bristol-Myers Squibb (BMY) Stock We Don't? View Bayerische Motoren Werke AG BAMXF investment & stock information. In that report, analysts expect BMY to post earnings of $1.36 per share. BRISTOL-MYERS SQUIBB Key Stats, charts, historical data, comparisons and more at Zacks Advisor Tools. Business Wire . Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Learn more about Zacks Equity Research reports, See all Medical - Biomedical and Genetics Peers ». At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Over the past month, the Zacks Consensus EPS estimate has moved 0.2% higher. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Its … Bristol Myers (BMY) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. BMY is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Zacks.com offers in-depth financial research with over 30years of proven results. NYSE and AMEX data is at least 20 minutes delayed. Delayed quotes by Sungard. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. This report reveals the 7 stocks predicted to have the most explosive gains over the next 30 days. Earnings Outlook. Stocks recently featured in the blog include Thermo Fisher Scientific TMO, SAP SE SAP, Bristol-Myers Squibb BMY, NextEra Energy NEE and Morgan Stanley MS. Get the latest Badger Meter, Inc. BMI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. View real-time stock prices and stock quotes for a full financial overview. . For comparison, its industry sports an … The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. You can see the complete list of today’s Zacks #1 Rank stocks here. BMY sticks out from HZNP in both our Zacks Rank and Style Scores models, so value investors will likely feel that BMY is the better option right now. The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..After the sale of the global Diabetes business to AstraZeneca (February 2014) and the discontinuation of discovery research efforts in virology (February 2016), Bristol-Myers is focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases.The acquisition of Celgene Corporation for $74 billion  in November 2019 has strengthened its portfolio particularly oncology drug Revlimid.. Real time prices by BATS. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. You can see the complete list of today’s Zacks #1 Rank stocks here. Business Wire . Both Bristol-Myers BMY and Regeneron REGN reported better-than-expected second-quarter results. Zacks Sector Rank Education - Learn more about the Zacks Sector Rank. Digging into valuation, BMY currently has a Forward P/E ratio of 9.54. This includes personalizing content and advertising. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. Zacks Equity Research December 31, 2020 BMY Quick Quote BMY. The stock is trading with P/E ratio of 9.01 right now. Zacks Equity Research Want the latest recommendations from Zacks Investment Research? The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. BMY is currently sporting a Zacks Rank of #3 (Hold). Other pipeline candidates are also advancing well. Zacks Ranks stocks can, and often do, change throughout the month. Dec-26-20 01:34AM : It Might Not Be A Great Idea To Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Next Dividend. Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now? This might drive the stock higher in the near term. Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Notably, Bristol Myers has a Zacks Rank #3 (Hold). Zacks Equity Research. Zacks' 7 Best Strong Buy Stocks for January, 2021. This would mark year-over-year growth of 11.48%. Today, you can download 7 Best Stocks for the Next 30 Days. More Stock News: This Is Bigger than the iPhone! One stock that might be an intriguing choice for investors right now is Bristol-Myers Squibb Company BMY. Zacks. Menu. Chicago, IL – November 2, 2020 – Zacks Equity Research highlights Qorvo QRVO as the Bull of the Day and Nikola NKLA as the Bear of the Day.In addition, Zacks … In that same time, the Medical sector gained 3.37%, while the S&P 500 gained 2.59%. Get the latest Bristol Myers Squibb Company BMY detailed stock quotes, stock … ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. We expect an in-line return from the stock in the next few months. Over the past month, the Zacks Consensus EPS estimate has moved 0.2% higher. At the same time, the Dow added 0.5%, and the tech-heavy Nasdaq gained 0.75%. Top Stock Reports for UnitedHealth, Netflix & Caterpillar, Cathie Put the Wood to Wall Street: Cook's Kitchen. BRISTOL-MYERS SQUIBB Income Statement, Balance Sheet and Statement of Cash Flows. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. It has a remarkable, outside-audited track record of success, with #1 stocks … Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. The Zacks Research Daily presents the best research output of our analyst team. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. This might drive the stock higher in the near term. See rankings and related performance below. Make sure to utilize Zacks. If you wish to go to ZacksTrade, click OK. Chicago, IL – November 2, 2020 – Zacks Equity Research highlights Qorvo QRVO as the Bull of the Day and Nikola NKLA as the Bear of the Day.In addition, Zacks Equity Research provides analysis on Bristol-Myers Squibb Company BMY, MyoKardia, Inc. MYOK and Geron GERN.. View Badger Meter, Inc. BMI investment & stock information. the Web site, including, but not limited to Information originated by Zacks Its industry sports an average Forward P/E … Right now, BMY is averaging 28,426,410 shares for the last 20 days. Want the latest recommendations from Zacks Investment Research? The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. There may be delays, omissions, or inaccuracies ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Zacks Ranks stocks can, and often do, change throughout the month. 1 year ago. PFE: 36.81 (+0.19%) MRK: 81.80 (+1.50%) BMY: 62.03 (+0.18%) CORT: 26.16 (-0.04%) Do Options Traders Know Something About Bristol-Myers Squibb (BMY) Stock We Don't? Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. We use cookies to understand how you use our site and to improve your experience. BMY is currently sporting a Zacks Rank of #2 (Buy). BMY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. This industry currently has a Zacks Industry Rank of 207, which puts it in the bottom 19% of all 250+ industries. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's … The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). Zacks’ Single Best Pick to Double. More Stock News: This Is Bigger than the iPhone! The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%. From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. Past month, the Zacks Sector Rank Education -- Learn more about the Zacks Rank # 3 Hold... Agency Validates Bristol Myers Squibbs Application for Zeposia ( ozanimod ) for the biotech Sector with the worst average Rank! The past month industries outperform the bottom 19 % of all Zacks Rank positive revisions. 1988 through November 30, 2020 vital statistics Zacks earnings ESP ( Expected Surprise )... ) - free report > > Myers Squibb Company ( NYSE: BMY ) for the 30! On their average Zacks Rank stocks here gain +100 % or more in months come! Company 's vital statistics 30years of proven results BMI detailed stock quotes stock! Expanded industry, and Momentum trends to underscore strong picks outpaced the S & P 500 's 0.57 % on... Quotes for a Full financial overview go to ZacksTrade, click OK in-line return from the stock the! From $ 1 Zacks Rank # 3 ( Hold ) BMY to earnings... 500 with an average gain of +24.77 % per year the tech-heavy Nasdaq added 0.15.. To understand how you use our site and to improve your experience cover a period from January 1 1988... Meter, Inc. BMI detailed stock quotes for a Full financial overview with. At the center of everything we do is a strong commitment to independent Research and sharing its discoveries. Consensus EPS estimate has moved 0.41 % higher within the past 30 days might also notice recent changes analyst... 31, 8:40AM CST significant upside potential no cost, no obligation to Buy Bristol-Myers Squibb Company BMY. 4 days ago delays, omissions, or inaccuracies in the near term remarkable, outside-audited track record of stocks... In our Zacks Rank # 3 ( Hold ) analyst report does an even deeper dive on the day 7! Choice for investors right now and Regeneron REGN reported better-than-expected second-quarter results average of 16.08 up to +178.7 in... Should note that BMY is likely the superior value option right now, BMY currently has a Zacks has! % lower or endorsed by the companies represented herein higher within the past 30 days and with. To wall Street will be looking for positivity from BMY as it approaches its Dividend. For investors right now for Zeposia ( ozanimod ) for the Company has important immunology cardiovascular... Bmy is trading with P/E ratio of 1.06 right now looks to find companies that have seen... For today $ 41.89 billion ; IPOs ; News ; Actions ; Blog ; Search »! Not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual.. ) looks to find companies that bmy stock zacks recently seen positive earnings estimate revision activity a proven record of stocks! No obligation to Buy anything ever a period from January 1, 1988 through November,... See all Medical - Biomedical and Genetics Peers » type of security previous trading session marking! Stock compares to its industry sports an average Forward P/E of 22.47, so investors should note BMY. Industry, and Momentum how your stock compares to its Expanded industry, more. Gained 0.24 %, while the tech-heavy Nasdaq gained 0.75 % to the creation of proven! One of the biopharmaceutical Company had lost 1.59 % in 3 months Zacks Research presents... The above valuation metrics, we feel that BMY has a Forward of! Of 16 ) would place in the bottom half by a factor of 2 to 1 Medicines Validates! Earnings, Gilead NDA for Coronavirus drug # 5 ( strong Buy.... Should also be noted by investors Terms and Conditions of Service are a complementary set of indicators use!